Status: Not yet recruiting
Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.
Participants needed: 135
Trial details
Phase: Phase 2Age: 50+Biological sex: AllType: InterventionalSponsor: CHA Vaccine Institute Co., Ltd.Updated: Mar 19, 2026Locations: 7
Eligibility criteria
Healthy adults aged 50 years or older [+3]
History of herpes zoster prior to screening [+7]